Your browser doesn't support javascript.
loading
Filarial nematode phenotypic screening cascade to identify compounds with anti-parasitic activity for drug discovery optimization.
Hawryluk, Natalie; Zhiru, Li; Carlow, Clotilde; Gokool, Suzanne; Townson, Simon; Kreiss, Tamara; Chojnowski, Agnieszka; Prorok, Monika; Siekierka, John; Ehrens, Alexandra; Koschel, Marianne; Lhermitte-Vallarino, Nathaly; Martin, Coralie; Hoerauf, Achim; Hernandez, Geraldine; Canan, Stacie; Khetani, Vikram; Zeldis, Jerome; Specht, Sabine; Hübner, Marc P; Scandale, Ivan.
Afiliação
  • Hawryluk N; Bristol Myers Squibb, San Diego, CA, USA. Electronic address: nataliehawryluk@gmail.com.
  • Zhiru L; New England Biolabs, Ipswich, MA, USA.
  • Carlow C; New England Biolabs, Ipswich, MA, USA.
  • Gokool S; Northwick Park Institute for Medical Research, London, UK.
  • Townson S; Northwick Park Institute for Medical Research, London, UK.
  • Kreiss T; Sokol Institute of Pharmaceutical Life Sciences, Montclair State University, Montclair, NJ, USA.
  • Chojnowski A; Sokol Institute of Pharmaceutical Life Sciences, Montclair State University, Montclair, NJ, USA.
  • Prorok M; Sokol Institute of Pharmaceutical Life Sciences, Montclair State University, Montclair, NJ, USA.
  • Siekierka J; Sokol Institute of Pharmaceutical Life Sciences, Montclair State University, Montclair, NJ, USA.
  • Ehrens A; Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Germany; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Bonn, Germany.
  • Koschel M; Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Germany.
  • Lhermitte-Vallarino N; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Bonn, Germany.
  • Martin C; Unité Molécules de Communication et Adaptation des Microorganismes (MCAM, UMR 7245), Muséum national d'Histoire naturelle, Paris, France.
  • Hoerauf A; Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Germany; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Bonn, Germany.
  • Hernandez G; Bristol Myers Squibb, San Diego, CA, USA.
  • Canan S; Bristol Myers Squibb, San Diego, CA, USA.
  • Khetani V; Bristol Myers Squibb, Summit, NJ, USA.
  • Zeldis J; Celgene Global Health, Summit, NJ, USA.
  • Specht S; Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Germany; Drugs for Neglected Diseases Initiative, Geneva, Switzerland.
  • Hübner MP; Institute for Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Germany; German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Bonn, Germany.
  • Scandale I; Drugs for Neglected Diseases Initiative, Geneva, Switzerland.
Article em En | MEDLINE | ID: mdl-35834918
ABSTRACT
Filarial diseases, including lymphatic filariasis and onchocerciasis, are considered among the most devastating of all tropical diseases, affecting over 86 million people worldwide. To control and more rapidly eliminate onchocerciasis requires treatments that target the adult stage of the parasite. Drug discovery efforts are challenged by the lack of preclinical animal models using the human-pathogenic filariae, requiring the use of surrogate parasites for Onchocerca volvulus for both ex vivo and in vivo evaluation. Herein, we describe a platform utilizing phenotypic ex vivo assays consisting of the free-living nematode Caenorhabditis elegans, microfilariae and adult filariae of the bovine filariae Onchocerca lienalis and Onchocerca gutturosa, respectively, as well as microfilariae and adult filariae of the feline filariae Brugia pahangi, the rodent filariae Litomosoides sigmodontis and the human-pathogenic filariae Brugia malayi to assess activity across various surrogate parasites. Utilization of those surrogate nematodes for phenotypic ex vivo assays in order to assess activity across various parasites led to the successful establishment of a screening cascade and identification of multiple compounds with potential macrofilaricidal activity and desirable physicochemical, MW = 200-400 and low lipophilicity, logP <4, and pharmacokinetic properties, rat and human liver S9 stability of ≥70% remaining at 60 min, and AUC exposures above 3 µM h. This platform demonstrated the successful establishment of a screening cascade which resulted in the discovery of potential novel macrofilaricidal compounds for futher drug discovery lead optimization efforts. This screening cascade identified two distinct chemical series wherein one compound produced a significant 68% reduction of adult Litomosoides sigmodontis in the mouse model. Successful demonstration of efficacy prompted lead optimization medicinal chemistry efforts for this novel series.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oncocercose / Parasitos / Brugia Malayi Tipo de estudo: Diagnostic_studies / Screening_studies Limite: Adult / Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oncocercose / Parasitos / Brugia Malayi Tipo de estudo: Diagnostic_studies / Screening_studies Limite: Adult / Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article